Financing ·
Elutia Inc. reported second quarter 2026 net sales of $2.4 million and a net loss of $7.6 million, while securing up…
ELUTElutia Inc.
Elutia Inc. reported second quarter 2026 net sales of $2.4 million and a net loss of $7.6 million, while securing up to $26 million in capital to fund its NXT-41x product through commercial launch without an equity offering. The financing includes a $15 million credit facility with $10 million funded at closing and an additional $11 million from the SimpliDerm business divestiture. Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and patients.